Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

November 22, 2023

Study Completion Date

December 31, 2025

Conditions

Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG

PD-1 blocking antibody

Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.

DRUG

Chemotherapy

Cisplatin and Gemcitabine

RADIATION

IMRT

IMRT 60-66Gy, 1.8-2.0Gy/f/day

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER